Glaukos Co. (NYSE:GKOS) COO Sells $498,700.80 in Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Glaukos Price Performance

NYSE GKOS opened at $151.22 on Wednesday. Glaukos Co. has a 12 month low of $74.75 and a 12 month high of $151.92. The firm has a market capitalization of $8.34 billion, a PE ratio of -50.07 and a beta of 1.03. The company’s 50 day simple moving average is $138.89 and its 200 day simple moving average is $128.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the previous year, the business earned ($0.50) EPS. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. As a group, equities research analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on GKOS shares. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Stifel Nicolaus raised their price target on Glaukos from $145.00 to $153.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Piper Sandler set a $140.00 price objective on Glaukos in a research report on Thursday, October 17th. Finally, Truist Financial increased their target price on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $145.92.

Institutional Investors Weigh In On Glaukos

Institutional investors and hedge funds have recently bought and sold shares of the business. HighTower Advisors LLC raised its holdings in shares of Glaukos by 3.3% in the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock worth $416,000 after purchasing an additional 103 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Glaukos in the third quarter valued at $25,000. New York State Teachers Retirement System lifted its position in shares of Glaukos by 0.4% during the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after acquiring an additional 200 shares during the last quarter. KBC Group NV boosted its stake in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares in the last quarter. Finally, Inspire Investing LLC boosted its stake in shares of Glaukos by 6.9% during the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after acquiring an additional 206 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.